Musings from The Power List: Michael May
CCRM CEO Michael May on quantum computing, commercialization, and the next era of cell therapy
Clinical Scorecard: Musings from The Power List: Michael May
At a Glance
Category Detail
Condition Cell and Gene Therapy Key Mechanisms Biomanufacturing, AI/ML, Quantum Computing, Digital Twins Target Population Patients requiring advanced therapies Care Setting Clinical development and manufacturing environments
Key Highlights
Establishment of DeepTech Bio Lab to explore advanced therapy industrialization. Access to capital is a significant bottleneck in cell and gene therapy. Progress in reprogramming induced pluripotent stem cells (iPSCs) for therapy. The allogeneic paradigm is crucial for mass adoption of therapies. Future drug development will be driven by data and AI. Guideline-Based Recommendations
Diagnosis
Evaluate therapeutic headroom associated with products. Management
Demonstrate clinical efficacy quickly to attract investment. Monitoring & Follow-up
Regularly assess the balance of benefit, cost, and risk of therapies. Risks
Potential for products to fail to meet commercial and adoption expectations. Patient & Prescribing Data
Patients with conditions treatable by cell and gene therapies.
Therapies may be personalized or bulk-manufactured depending on the indication.
Clinical Best Practices
Leverage collective knowledge in regulatory processes. Utilize in silico modeling for future medicine development. Related Resources & Content
